|

IBI363 Clinical Trials

7 actively recruiting trials across 2 locations

Also known as: IBI325, Lenvatinib

Other5 trials

A Study of IBI363 in Subjects With Advanced Melanoma
Phase 2
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Phase 2
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Phase 2
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Phase 1
The Efficacy and Safety of IBI363 in Solid Tumors
Phase 1/2

Fountain Valley, California1 trial

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

Memorial Health Services

Phase 3

San Francisco, California1 trial

A Study of IBI363 in Subjects with Advanced Solid Malignancies

University of California, San Francisco (UCSF)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.